These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
554 related items for PubMed ID: 17701197
1. Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration. Ladewig MS, Karl SE, Hamelmann V, Helb HM, Scholl HP, Holz FG, Eter N. Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):17-25. PubMed ID: 17701197 [Abstract] [Full Text] [Related]
2. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Costa RA, Jorge R, Calucci D, Melo LA, Cardillo JA, Scott IU. Graefes Arch Clin Exp Ophthalmol; 2007 Sep; 245(9):1273-80. PubMed ID: 17333238 [Abstract] [Full Text] [Related]
3. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Lazic R, Gabric N. Ophthalmology; 2007 Jun; 114(6):1179-85. PubMed ID: 17544776 [Abstract] [Full Text] [Related]
4. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Dhalla MS, Shah GK, Blinder KJ, Ryan EH, Mittra RA, Tewari A. Retina; 2006 Jun; 26(9):988-93. PubMed ID: 17151484 [Abstract] [Full Text] [Related]
5. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. Bashshur ZF, Schakal A, Hamam RN, El Haibi CP, Jaafar RF, Noureddin BN. Arch Ophthalmol; 2007 Oct; 125(10):1357-61. PubMed ID: 17923543 [Abstract] [Full Text] [Related]
6. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Kaiser PK, Registry of Visudyne AMD Therapy Writing Committee, Boyer DS, Garcia R, Hao Y, Hughes MS, Jabbour NM, Kaiser PK, Mieler W, Slakter JS, Samuel M, Tolentino MJ, Roth D, Sheidow T, Strong HA. Ophthalmology; 2009 Apr; 116(4):747-55, 755.e1. PubMed ID: 19243834 [Abstract] [Full Text] [Related]
7. Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration. Smith BT, Dhalla MS, Shah GK, Blinder KJ, Ryan EH, Mittra RA. Retina; 2008 May; 28(5):675-81. PubMed ID: 18463509 [Abstract] [Full Text] [Related]
8. Single-session photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Ahmadieh H, Taei R, Soheilian M, Riazi-Esfahani M, Ahadi H. Eur J Ophthalmol; 2008 May; 18(2):297-300. PubMed ID: 18320527 [Abstract] [Full Text] [Related]
9. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A. Retina; 2007 May; 27(4):432-8. PubMed ID: 17420694 [Abstract] [Full Text] [Related]
10. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Augustin AJ, Puls S, Offermann I. Retina; 2007 Feb; 27(2):133-40. PubMed ID: 17290193 [Abstract] [Full Text] [Related]
11. Bevacizumab vs photodynamic therapy for choroidal neovascularization in multifocal choroiditis. Parodi MB, Iacono P, Kontadakis DS, Zucchiatti I, Cascavilla ML, Bandello F. Arch Ophthalmol; 2010 Sep; 128(9):1100-3. PubMed ID: 20837791 [Abstract] [Full Text] [Related]
13. Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration. Bakri SJ, Couch SM, McCannel CA, Edwards AO. Retina; 2009 May; 29(5):573-8. PubMed ID: 19430278 [Abstract] [Full Text] [Related]
14. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245 [Abstract] [Full Text] [Related]